Bipolar Disorders - Zyprexa Sets the Mood for Revenue Growth

The bipolar disorder market is experiencing a renewed expansion in product life-cycle management. Presently, mood stabilizers are the basis of treatment, although the antipsychotics led by Zyprexa, are evolving as a new therapeutic strategy. Companies will have to differentiate their products in the increasingly crowded market if they wish to protect their market share. 

Scope

Analysis is based on a survey of 164 treating physicians in the seven major markets as well as in-depth interviews with Bipolar key opinion leaders 

Detailed treatment trees showing the prevalence, diagnosis and treatment rates of bipolar across the seven major markets 

Assessment of the use of mono- and combination-therapy in specific bipolar affective episodes 

Identification of therapeutic and diagnostic unmet needs, highlights areas where stakeholder investment is vital to drive patient identification 

Report Highlights

Datamonitor primary research has identified variances in class and brand prescribing preferences among physicians, according to BD type and geography; although prescribing trends generally follow recognized national and international guidelines. However, there is concern over the use of tricyclic antidepressants in bipolar depression. 

Only 48% of the BD population are accurately diagnosed. Datamonitor has highlighted a number of serious diagnostic issues, which infers that many of the patients currently diagnosed may receive incorrect BD categorization. 

Lilly’s Zyprexa is currently leading the bipolar market in terms of revenue and life cycle management, with recent approval for maintenance therapy and reformulation in a combination pill with Prozac as Symbyax. Other atypical antipsychotics appear to be following suit, and could threaten anticonvulsant dominance of mood stabilization. 

Reasons to Purchase

Understand differential treatment unmet needs in key patient populations identified by sex, co-morbidities and bipolar disorder type 

Gain expert insight into current diagnostic unmet needs and key growth areas in the public and healthcare sectors  

Target physicians more effectively, through an understanding of prescribing behavior 

February 2004 Pages: 250 

Publisher: Datamonitor CNS Central Nervous System 2004 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS_Central_Nervous_System_2004.html#a537